Abstract
We studied 122 stool samples collected from 25 patients with hematologic malignancies who received prophylactic norfloxacin. Fecal samples were obtained at admission and twice weekly thereafter during prophylaxis. Fluoroquinolone-resistant Escherichia coli strains were isolated from the feces of 10 (40%) of the patients; two patients had fluoroquinolone-resistant E. coli strains prior to beginning norfloxacin treatment, and in the other eight patients, the strains appeared subsequently. One patient developed fluoroquinolone-resistant E. coli bacteremia after 10 days of norfloxacin administration.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adolescent
-
Adult
-
Aged
-
Anti-Infective Agents / pharmacology
-
Anti-Infective Agents / therapeutic use*
-
DNA, Bacterial / analysis
-
Drug Resistance, Microbial / genetics
-
Electrophoresis, Gel, Pulsed-Field
-
Escherichia coli / drug effects*
-
Escherichia coli / genetics
-
Feces / microbiology*
-
Female
-
Humans
-
Leukemia / drug therapy
-
Lymphoma / drug therapy
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy
-
Neoplasms / drug therapy*
-
Neoplasms / microbiology
-
Norfloxacin / therapeutic use*
-
Opportunistic Infections / prevention & control*
Substances
-
Anti-Infective Agents
-
DNA, Bacterial
-
Norfloxacin